Appendix Cancer Treatment
Treatment for Appendiceal Cancer
Surgery, CRS, HIPEC, Systemic Chemotherapy
Find an Appendix Cancer Treatment Specialist!
What is the treatment for appendiceal cancer?
Pal, Jeanie cancer free 10+ years!
The obvious goal for any cancer therapy and treatment is to increase and improve your options for long term survival. Treatment with the best specialist, focused on attending to your specific diagnosis, may increase your opportunities for survival!
Your surgical oncologist specialist will explain and review all treatment options for Appendix cancer. Your treatment plan will depend on your overall health, the type of tumor (pathology), the quantity (mass) size and location of the tumor, and whether the cancer has metastasized.
Each patient's case is unique. Most patients live productive and healthy lives following treatment!Treatment may include surgery and/or chemotherapy (systemic, HIPEC or both.)
Pal, Jim, cancer free 5+ years!
What is the treatment for Appendix Cancer?
How is Appendix Cancer treated?
What are Appendiceal Cancer treatments?
Are you or a loved one preparing for surgery for Appendix Cancer treatment?
The PMP Pals' Network provides a wide variety of services to assist you in preparing for, and recuperating from, appendix cancer treatment and surgery as quickly as possible!
Our Preparing for Surgery Handbook and our weekly Newsletters provide step by step instructions to assist you with planning for your appendix cancer treatment!
Our Pal Mentors will personally communicate with you via telephone, email, personal visits, SKYPE or web cam to help you, or your loved one prepare for surgery and/or HIPEC. We will share helpful resources and positive information to guide you through your recuperation!
We are here to assist you in returning to your full and active life, following treatment, as soon as possible!
Don't forget to review our Pal Profiles and to view just a few of the Pal Mentors who are ready to help YOU!
Pal Mentors help you navigate through treatment!
Whether you're treatment includes surgery or chemotherapy, our Pal Mentors are ready to assist you!
Join the Pals and connect with our Appendix Cancer Mentors today!
Surgery
Treatment for Appendix Cancer, Pseudomyxoma Peritonei syndrome, and other Peritoneal Surface Malignancies generally includes CRS (cytoreductive surgery) with or without systemic chemotherapy or HIPEC.
HIPEC (hyperthermic intraperitoneal chemotherapy) may be administered when complete removal of visible tumor (or debulking) is achieved through cytoreductive surgery. HIPEC involves perfusion of the peritoneal cavity with chemotherapy heated to approximately 40 degrees Celsius.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) may be included at the conclusion of the cytoreductive surgery for the treatment of pseudomyxoma peritonei and appendix cancer if substantial tumor debulking is accomplished through CRS.
HIPEC is administered with the infusion of heated chemotherapy during the last 90 minutes of the CRS procedure. Through HIPEC the surgeon(s) intend to destroy any residual tumor cells that may not have been surgically removed during CRS.
HIPEC treatment includes the infusion of the abdominal cavity with a specific chemotherapy, heated to approximately 40 degrees Celsius for a period of approximately 90 minutes. The purpose of the HIPEC treatment is to attempt to kill any tumor cells which were not removed during the actual surgery process..
Although this procedure may initially sound overwhlming to the newly diagnosed patient, rarely is resection and/or removal of all of these organs is required.
Each patient's case is unique/ Most patients live productive and healthy lives following surgery!
HIPEC (hyperthermic intraperitoneal chemotherapy) may be administered when complete removal of visible tumor (or debulking) is achieved through cytoreductive surgery. HIPEC involves perfusion of the peritoneal cavity with chemotherapy heated to approximately 40 degrees Celsius.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) may be included at the conclusion of the cytoreductive surgery for the treatment of pseudomyxoma peritonei and appendix cancer if substantial tumor debulking is accomplished through CRS.
HIPEC is administered with the infusion of heated chemotherapy during the last 90 minutes of the CRS procedure. Through HIPEC the surgeon(s) intend to destroy any residual tumor cells that may not have been surgically removed during CRS.
HIPEC treatment includes the infusion of the abdominal cavity with a specific chemotherapy, heated to approximately 40 degrees Celsius for a period of approximately 90 minutes. The purpose of the HIPEC treatment is to attempt to kill any tumor cells which were not removed during the actual surgery process..
Although this procedure may initially sound overwhlming to the newly diagnosed patient, rarely is resection and/or removal of all of these organs is required.
Each patient's case is unique/ Most patients live productive and healthy lives following surgery!
Meet "Pals" who have successfully recuperated from surgery!
"Pals" from around the world!
Questions to Ask Your Surgeon
The PMP Pals’ Network suggests that patients prepare a personal list of questions prior to meeting with a surgeon for a pre op evaluation.
Here are a few questions for your consideration.
Refer to the PMP Pals’ Handbooks, Preparing for a Consultation with a Specialist and Preparing for Surgery for detailed lists of questions to ask your physician.
Treatment
Is my diagnosis aggressive? Does it require treatment?
What are my treatment options for my particular diagnosis?
If you were me, which option would you choose and why?
What is my prognosis with the treatment you recommend?
What is my prognosis without treatment?
What does “watch and wait” mean?
Surgery
Will any organs be removed?
If so, what, if any, are the ramifications of losing those organs?
Will I have an ostomy? If so, which type? Ileostomy? Colostomy? Urostomy?
If I have an ostomy, can it be “reversed?” If so, when?
Will I have the HIPEC treatment? Is HIPEC optional?
How will my pain be controlled after surgery?
What, if any, are the risks/complications from this surgery? From HIPEC?
Will the HIPEC treatment and your fees as my attending surgeon covered by my insurance?
Post Op (After Surgery)
Will my family caregiver be able to visit me in the ICU?
How often will you visit me during my hospitalization?
Who will oversee my post op recuperation? You (my attending surgeon) or the Fellows or Residents?
How long will I be hospitalized?
When will I be able to return to work?
When will I be able to return to work?
Surgeon’s Experience
How many patients with my diagnosis do you treat each year?
How many surgeries have you performed on patients with conditions like mine?
How often do you treat patients with the HIPEC procedure?
How experienced is your surgical team and post op nursing staff in treating patients with my condition?
Answers to your questions!
How are Patients Selected for Surgery?
Patient Selection
This question is frequently asked by newly diagnosed patients and “veteran” patients experiencing a “recurrence of disease.”
Why are some patients accepted for CRS or CRS/HIPC while others are not?
Is there any truth to the rumors that surgeons “cherry pick” their patients?
Why isn’t every patient a candidate for surgery?
Surgeons refer to the process of evaluating a surgical candidate as “patient selection.”
Many factors are taken into consideration for patient selection.
The success of CRS and HIPEC may be dependent on the:
patient’s overall general health,
complete removal of all tumor tissue,
location of tumor site(s) and
type of tumor (histology and differentiation.)
The following is a very general explanation of how patients are selected as surgical candidates:
1. Preliminary disease criteria
Patients with metastasis to the peritoneum, aka Peritoneal Carcinomatosis.
Patients with disease contained within the abdomen (without metastasis outside the abdomen)
2. Preliminary general health criteria for patient selection
Good overall heath lacking any major co-morbid conditions*.
Age (some surgeons limit the ages of patients they will accept into surgery)
Mental health (coherence, ability to understand instructions, evidence of chemical dependencies, etc.)
Ability to pay for surgery (adequate health insurance coverage or ability to pay out-of-pocket for medical care)
3. Preliminary review of patient medical history
Medical history including surgical history, if applicable, co-morbid conditions* (ie diabetes, lung or heart disease) current medications (prescribed and OTC) allergies and family history
History of present illness including summary of symptoms
Operative reports of previous surgeries
Pathology reports
Record of previous chemotherapy and radiotherapy treatments, if applicable, including dates and protocols
4. Extent of disease
Evaluation of CT scans to determine PCI (Peritoneal Cancer Index.)
The PCI helps the surgeon to determine the extent, volume and locations of the disease.
Evaluation of tumor block samples from original surgery(ies) if applicable.
Laparoscopy optional
Biopsy optional
Evaluation of tumor markers and associated lab tests
Physical examination of the patient
Recommended Reading
Chemotherapy Following CRS for Appendix Cancer
Dr Garrett Nash
Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Appendiceal Mucinous Neoplasms With Isolated Peritoneal Metastasis
Wagner, Patrick L. M.D.1; Jones, Douglas M.D.1; Aronova, Anna M.D.1; Shia, Jinru M.D.2; Weiser, Martin R. M.D.1; Temple, Larissa K. M.D.1; Chung, Ki Y. M.D.3; O'Reilly, Eileen M. M.D.3; Kelsen, David M.D.3; Paty, Philip B. M.D.1; Nash, Garrett M. M.D., M.P.H.1
BACKGROUND: Although cytoreductive surgery and intraperitoneal chemotherapy have been advocated as standard treatment for appendiceal neoplasms with isolated peritoneal metastasis, the optimal method of chemotherapy administration has not been established. At our institution, patients undergoing complete cytoreduction in this setting typically receive multiple cycles of early postoperative intraperitoneal chemotherapy.
OBJECTIVES: The aim of this study was to describe patients with appendiceal neoplasms and peritoneal dissemination treated with complete cytoreductive surgery and early postoperative intraperitoneal chemotherapy and to document associated time to progression and morbidity.
DESIGN: This is a retrospective study at a single specialty institution. Hospital and departmental databases were searched for patients presenting with primary appendiceal neoplasms undergoing cytoreductive surgery, placement of intraperitoneal port, and subsequent intraperitoneal chemotherapy from June 1995 to September 2009.
SETTINGS: This study was conducted at Memorial Sloan-Kettering Cancer Center.
PATIENTS: We identified 50 patients (30 female), median age 48 (range, 26–66) who met the criteria.
INTERVENTIONS: Cytoreductive surgery, placement intraperitoneal port, and intraperitoneal chemotherapy were performed.
RESULTS: All patients underwent intraperitoneal catheter placement after complete cytoreductive surgery, followed by a median of 4 cycles (range, 1–9) intraperitoneal 5-fluoro-2′-deoxyuridine (1000 mg/m2 daily for 3 days) plus leucovorin (240 mg/m2). The median hospital length of stay was 9 days (maximum, 29). Thirty-four percent of the patients experienced complications; 12% experienced major complications (3 abdominal abscesses, 1 deep vein thrombosis, 1 abdominal hemorrhage, and 1 intraperitoneal port malfunction). There were no 30-day mortalities. Five-year recurrence-free interval was observed in 43%. Among 23 patients with recurrence, 18 had a recurrence only within the peritoneum. The median overall survival was 9.8 years.
LIMITATIONS: This is a retrospective study. Many patients had surgery first at other institutions; therefore, pathologic examination of resected material was not possible in every case. Other factors possibly impacting time to recurrence (ie, preoperative chemotherapy, duration between onset of disease and presentation to our institution) varied among patients and were not controlled for. In the absence of a control arm undergoing complete cytoreduction without early postoperative intraperitoneal chemotherapy, we did not ascertain whether intraperitoneal chemotherapy confers additional benefit.
CONCLUSIONS: Cytoreductive surgery plus multiple cycles of early postoperative intraperitoneal chemotherapy is safe, achieving survival results similar to published outcomes of other protocols (including hyperthermic intraperitoneal chemotherapy). Prospective trials are warranted to compare various methods of intraperitoneal chemotherapy in this setting.
SOURCE:
Diseases of the Colon & Rectum: April 2012 - Volume 55 - Issue 4 - p 407–415
doi: 10.1097/DCR.0b013e3182468330
doi: 10.1097/DCR.0b013e3182468330
Laparoscopic vs Open Distal Gastrectomy
Laparoscopy-Assisted Versus Open Distal Gastrectomy for Early Gastric Cancer: Evidence from Randomized and Nonrandomized Clinical Trials
Zeng, Yi-Ke MD; Yang, Zu-Li MD, PhD; Peng, Jun-Sheng MD, PhD; Lin, Han-Sheng MM; Cai, Ling BS
Source: Annals of Surgery:
POST AUTHOR CORRECTIONS, 1 June 2012
doi: 10.1097/SLA.0b013e3182583e2e
Meta-Analysis: PDF Only
Abstract
Objective: To evaluate the safety and efficacy of laparoscopy-assisted distal gastrectomy (LADG) in patients with early gastric cancer (EGC) to determine whether LADG is an acceptable alternative to open distal gastrectomy (ODG).
Background: LADG combined with less than D2 or D2 lymphadenectomy for EGC is still a controversial surgical intervention for its uncertain oncological safety and economic benefit. We conducted this systematic review and meta-analysis that included randomized control trials (RCTs) and non-RCTs of LADG versus ODG to evaluate whether the safety and efficacy of LADG in patients with EGC are equivalent to those of ODG.
Methods: A comprehensive search of PubMed, EMBASE, Cochrane Library, and China Knowledge Resource Integrated Database was performed. Eligible trials published between January 1, 1994, and December 31, 2010, were included in the study. Data synthesis and statistical analysis were carried out by RevMan 5.0 software. The quality of evidence was assessed by GRADEpro 3.2.2.
Results: Twenty-two studies with 3411 participants were included in this study.
The mean number of lymph nodes retrieved in LADG was close to that retrieved in ODG (in the less than D2 resection: weighted mean difference [WMD] = -1.79; 95% confidence interval [95% CI], -5.78 to 2.19; P = 0.38; heterogeneity: P < 0.00001, I2 = 98%; and in the D2 resection: WMD = -1.53; 95% CI, -3.56 to 0.51; P = 0.14; heterogeneity: P = 0.23, I2 = 26%). The overall postoperative morbidity was significantly less in LADG than in ODG (relative risk = 0.58; 95% CI, 0.46-0.74; P < 0.00001; heterogeneity: P = 0.94, I2 = 0%). LADG reduced the intraoperative blood loss, postoperative analgesic consumption, and hospital duration, without increasing the total hospitalization costs and cancer recurrence rate. The long-term survival rate of patients undergoing LADG was similar to that of patients undergoing ODG. However, LADG was still a technically dependent and time-consuming procedure. Conversion rate of LADG was 0% to 2.94%. The reported reasons for conversion were bleeding, adhesion, and safety resection margin requirement.
Limitations: There were potential biases and significant heterogeneity in some clinical outcome measures in this study. Methodologically high-quality controlled clinical trials were sparse for this new surgical intervention. According to The Grading of Recommendations Assessment, Development and Evaluation approach, when assessing the safety and efficacy of LADG by comparing with those of ODG with the defined clinical outcomes in patients with EGC, the quality of the currently available clinical evidence was very low.
Conclusions: LADG may be a technically feasible alternative for EGC when it is performed in experienced surgical centers in which patients undergoing LADG may benefit from the faster postoperative recovery. However, the currently available evidence cannot exclude the potential clinical benefits or harms, especially in the node-positive cases. Methodologically high-quality comparative studies are needed for further evaluation.
(C) 2012 Lippincott Williams & Wilkins, Inc.
Hospital Safety and Quality of Care
Is Patient Safety at Risk in Too Many Hospitals?
Consumer Reports Rates Hospitals; Finds Too Many Pose Safety Risks to Patients
Source: Consumer Reports .07.05.12
Ratings Describe Some Hospitals Riskier Than Others
Source: Consumer Reports 07.05.12
Ten Things You Can Do to Be a Safe Patient in the Hospital
Ten Things You can do to be a Safe Patient in the Hospital
Source: CDC
Learn suggestions for preparing for surgery, preventing infections, advocating for your own care, taking antibiotics and other medications, central lines, urinary catheters, and more!
Source: CDC
Learn suggestions for preparing for surgery, preventing infections, advocating for your own care, taking antibiotics and other medications, central lines, urinary catheters, and more!
Hospitals & Health Systems with Great Oncology Programs
Becker's Hospital Review has named "70 Hospitals and Health Systems With Great Oncology Programs." These hospitals are on the cutting edge of cancer treatment, prevention and research, and the Becker's Hospital Review editorial team selected them based on clinical accolades, quality care and contributions to the field of oncology.
The PMP Pals’ Network has condensed this list to include those hospitals programs and who have been vetted by the PMP Pals’ Network, and whose surgical oncologists are listed on our international HIPEC Treatment Centers page.
The PMP Pals’ Network HIPEC Treatment Centers page lists other cancer treatment centers that have been vetted by the Network but do not appear on the Becker’s Hospital Review list.
These hospitals have been recognized for excellence in this specialty by reputable healthcare rating resources, including U.S. News & World Report, HealthGrades, Thomson Reuters, the National Cancer Institute, the American College of Surgeons and the American Nurses Credentialing Center. They have demonstrated continual innovation in treatments and services, patient-centered care and the achievement of clinical milestones and groundbreaking discoveries.
The PMP Pals’ Network reminds patients and family caregivers that he following content should be used for informational purposes only and is not intended to substitute professional medical advice. The PMP Pals’ Network neither solicits, nor receives, funding or advertising revenue from cancer treatment centers, pharmaceutical companies, physicians who treat cancer or government agencies.
The following hospitals from Becker's are listed in alphabetical order with PMP Pals' Network vetted HIPEC Treatment specialists below each hospital's paragraph.
For an extended international listing of additional HIPEC Treatment specialists vetted by the PMP Pals Network, click here.
Our thanks to Becker's Review for sharing their listing with the public.
The PMP Pals’ Network has condensed this list to include those hospitals programs and who have been vetted by the PMP Pals’ Network, and whose surgical oncologists are listed on our international HIPEC Treatment Centers page.
The PMP Pals’ Network HIPEC Treatment Centers page lists other cancer treatment centers that have been vetted by the Network but do not appear on the Becker’s Hospital Review list.
These hospitals have been recognized for excellence in this specialty by reputable healthcare rating resources, including U.S. News & World Report, HealthGrades, Thomson Reuters, the National Cancer Institute, the American College of Surgeons and the American Nurses Credentialing Center. They have demonstrated continual innovation in treatments and services, patient-centered care and the achievement of clinical milestones and groundbreaking discoveries.
The PMP Pals’ Network reminds patients and family caregivers that he following content should be used for informational purposes only and is not intended to substitute professional medical advice. The PMP Pals’ Network neither solicits, nor receives, funding or advertising revenue from cancer treatment centers, pharmaceutical companies, physicians who treat cancer or government agencies.
The following hospitals from Becker's are listed in alphabetical order with PMP Pals' Network vetted HIPEC Treatment specialists below each hospital's paragraph.
For an extended international listing of additional HIPEC Treatment specialists vetted by the PMP Pals Network, click here.
Our thanks to Becker's Review for sharing their listing with the public.
Appendix Cancer Treatment Centers, USA
Froedtert Hospital (Milwaukee)
Froedtert Hospital's Clinical Cancer Center includes more than 200 oncologists, physicians and scientists in 13 disease-specific cancer programs. The center operates under a patient-centered "hub model," where physicians are grouped by the kinds of cancer they treat, not the type of service they provide.
It was recognized as a regional leader in cancer care in U.S. News & World Report's 2011 Best Hospitals list. The hospital, which uses tumor boards to develop patient-specific treatment plans, is also part of a cancer care network with two other local hospitals.
Dr T Clark Gamblin
Dr Kiran Turaga
It was recognized as a regional leader in cancer care in U.S. News & World Report's 2011 Best Hospitals list. The hospital, which uses tumor boards to develop patient-specific treatment plans, is also part of a cancer care network with two other local hospitals.
Dr T Clark Gamblin
Dr Kiran Turaga
Montefiore Medical Center (Bronx, N.Y.)
The Montefiore Einstein Center for Cancer Care is partnered for research with the Albert Einstein Cancer Center, which was one of the first cancer centers to receive National Cancer Institute designation in 1972.
Steven K Libutti
Roswell Park Cancer Institute (Buffalo, N.Y.)
Founded in 1898, Roswell Park was the country's first cancer center and remains the first and only facility in upstate New York designated as a Comprehensive Cancer Center by the National Cancer Institute.
It's accredited by the National Comprehensive Cancer Center Network, the American College of Surgeons Commission on Cancer and several other oncology-related organizations. Its patient satisfaction scores are consistently well-above the national average. In the past 10 years, the center has added more than 1,000 new jobs, dedicated an entire hospital facility to Phase I cancer research and formed international strategic partnerships with researchers.
Dr John Kane
It's accredited by the National Comprehensive Cancer Center Network, the American College of Surgeons Commission on Cancer and several other oncology-related organizations. Its patient satisfaction scores are consistently well-above the national average. In the past 10 years, the center has added more than 1,000 new jobs, dedicated an entire hospital facility to Phase I cancer research and formed international strategic partnerships with researchers.
Dr John Kane
University of Arizona Medical Center (Tucson)
University of Arizona Medical Center is the clinical affiliate of University of Arizona Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center established in 1976.
ACC patients receive inpatient and outpatient care from the UA Medical Center physicians. ACC is home to more than 300 oncologists and scientists, and it was recently awarded more than $19.5 million in grants to study skin cancer and colorectal cancer. It also offers the only genetic counselor in Tucson who specializes in cancer.
See Dr Evan S Ong
ACC patients receive inpatient and outpatient care from the UA Medical Center physicians. ACC is home to more than 300 oncologists and scientists, and it was recently awarded more than $19.5 million in grants to study skin cancer and colorectal cancer. It also offers the only genetic counselor in Tucson who specializes in cancer.
See Dr Evan S Ong
University of Maryland Medical Center (Baltimore)
The Marlene and Stewart Greenebaum Cancer Center is a National Cancer Institute-designated cancer center and is also accredited by the American College of Surgeons Commission on Cancer. The center also has major partnerships with the state of Maryland, the American Cancer Society and other cancer organizations in the private industry.
Dr Richard H Alexander
University of Pittsburgh Medical Center
UPMC partners in cancer care with the University of Pittsburgh Cancer Institute, which combines UPMC's medical expertise with the academic research at the University of Pittsburgh.
UPMC Cancer Centers include more than 1,700 physicians, scientists and other healthcare professionals in 14 areas of expertise on specific types or treatments of cancer. The Hillman Cancer Center, a five-story facility located on the UPMC Shadyside campus, is the flagship facility for the UPMC Cancer Centers network. UPMC received nearly $174 million in government funding for cancer research in 2011, making it the National Cancer Institute's 12th most-funded research institution.
Dr Steven A Ahrendt
See Dr David L Bartlett
Dr M Haroon Asif Choudry
Dr Matthew P Holtzman
Dr James F Pingpank
Dr Herbert J Zeh
Dr Amer H Zureikat
UC San Diego Medical Center (San Diego)
The UC San Diego Moores Cancer Center was established in 1979 and received designation from the National Cancer Institute as a Comprehensive Cancer Center in 2001.
Moores Cancer Center emphasizes a shared focus on bench-to-bedside research, preventive care and multidisciplinary treatment and has made waves in the field of cancer care. Its researchers pioneered intraperitoneal chemotherapy, which delivers high doses of anti-cancer drugs directly to ovarian tumors. In 2006, the federal government named that procedure, IP chemotherapy, as the new standard of treatment for ovarian cancer.
Dr Andrew M Lowy
University of Texas MD Anderson Cancer Center (Houston)
MD Anderson ranks first in the country for number of grants awarded and total amount of grant dollars from the National Cancer Institute.
Some of the largest strides in cancer research have occurred within the walls of MD Anderson. In the 1970s, researchers proved that metastasis is a non-random process. The center also pioneered chemotherapy in outpatient settings in the 1980s and early 1990s; a practice that is widely followed today and is more cost-effective for patients.
Dr Keith F Fournier
Dr Paul Mansfield
Wake Forest Baptist Medical Center (Winston-Salem, N.C.)
The Comprehensive Cancer Center at Wake Forest Baptist is home to more than 120 clinicians and oncologists with expertise in all aspects among the cancer continuum. The center is the first in the region to be fully accredited by the National Accreditation Program for Breast Centers, and the National Cancer Institute has also designated Wake Forest as a comprehensive cancer center.
Dr Edward A Levine
Dr Perry Shen
Dr John Stewart IV
Aggressive Management and Treatment of Peritoneal Carcinomatosis from Appendiceal Neoplasms
Dr David L Bartlett
Aggressive Management of Peritoneal Carcinomatosis from Mucinous Appendiceal Neoplasms
Frances Austin MD, Arun Mavanur MD, Magesh Sathaiah, Jennifer Steel PhD, Diana Lenzner MS, Lekshmi Ramalingam MD, Matthew Holtzman MD, Steven Ahrendt MD, James Pingpank MD, Herbert J. Zeh MD, David L. Bartlett MD, Haroon A. Choudry MD Regional Cancer Therapies, February 2012
Abstract
Background
Peritoneal carcinomatosis (PC) in the setting of mucinous appendiceal neoplasms is characterized by the intraperitoneal accumulation of mucinous ascites and mucin-secreting epithelial cells that leads to progressive compression of intra-abdominal organs, morbidity, and eventual death. We assessed postoperative and oncologic outcomes after aggressive surgical management by experienced surgeons.
Methods
We analyzed clinicopathologic, perioperative, and oncologic outcome data in 282 patients with PC from appendiceal adenocarcinomas between 2001 and 2010 from a prospective database. Kaplan–Meier survival curves and multivariate Cox-regression models were used to identify prognostic factors affecting oncologic outcomes.
Results
Adequate cytoreduction was achieved in 82% of patients (completeness of cytoreduction score (CC)-0: 49%; CC-1: 33%). Median simplified peritoneal cancer index (SPCI), operative time, and estimated blood loss were 14 (range, 0–21), 483.5 min (range, 46–1,402), and 800 ml (range, 0–14,000), respectively. Pathology assessment demonstrated high-grade tumors in 36% of patients and lymph node involvement in 23% of patients. Major postoperative morbidity occurred in 70 (25%) patients. Median overall survival was 6.72 years (95% confidence interval (CI), 4.17 years not reached), with 5 year overall survival probability of 52.7% (95% CI, 42.4, 62%). In a multivariate Cox-regression model, tumor grade, age, preoperative SPCI and chemo-naïve status at surgery were joint significant predictors of overall survival. Tumor grade, postoperative CC-score, prior chemotherapy, and preoperative SPCI were joint significant predictors of time to progression.
Conclusions
Aggressive management of PC from mucinous appendiceal neoplasms, by experienced surgeons, to achieve complete cytoreduction provides long-term survival with low major morbidity.
Appendix Cancer Treatment Definitions
Dr Paul H Sugarbaker
List of Abbreviations Describing Surgery and HIPEC as provided to the PMP Pals' Network by Dr Paul Sugarbaker
· CS – Chemosurgery (most general abbreviation includes CRS, HIPEC, EPIC and ABC)
· HIPEC – Hyperthermic intraperitoneal chemotherapy
· HIPEC + 5FU – Hyperthermic intraperitoneal chemotherapy plus intravenous 5-fluorouracil
· HIPEC + IFO – Hyperthermic intraperitoneal chemotherapy plus intravenous ifosfamide
· EPIC – Early postoperative intraperitoneal chemotherapy usually 5-FU or paclitaxel
·
· ABC – Adjuvant bidirectional chemotherapy
· CRS – Cytoreductive surgery
· CCRS – Complete cytoreductive surgery
· PM – Peritoneal metastases (should replace PC)
· PC – Peritoneal carcinomatosis
· POC – Perioperative chemotherapy
· LM – Liver metastases
· LNM – Lymph node metastases
· LR – Local-regional
· IP port – Intraperitoneal port used for ABC
· Tenckhoff catheter – Temporary catheter used to deliver EPIC
Tips to Fight Cancer Fatigue!
Amy Kalman, RN
Tips to Fight Cancer Fatigue: Cancer Realities from Diagnosis to Treatment
Source: Amy Kalman RN 01.27.12
Amy addresses concerns about sleep deprivation and other sources of fatigue during cancer treatment and recuperation.
Appendix Cancer Surgery
Surgery for the Treatment of Appendiceal Cancer
Photo courtesy of Dr Marcello Deraco
Appendix Cancer Surgery
Appendectomy refers to the surgical removal of the appendix. Appendectomies may be performed via laparscopy. (View Laparoscopic appendectomy slideshow, presented by Nucleus)
Debulking surgery: The purpose of debulking surgery for appendix cancer treatment is to remove as much tumor as possible. Debulking often includes the removal of the omentum and the right colon. Additionally, for women, debulking will likely include a hysterectomy, if this was not previously performed. Adhesions may more troublesome with any additional debulking surgeries.
CRS (cytoreductive surgery) consists of the removal of as much mucin and visible tumor as possible, from the abdominal or peritoneal cavity. Cytoreductive surgery refers to the removal of all visible tumors.
Cytoreductive Surgery includes thorough removal or destruction of all visible tumors throughout the surfaces of the peritoneum. Surgery may include the removal of segments of small and large bowel, gall bladder, liver, omentum, ovaries, pancreas, spleen, stomach and uterus.
Cytoreductive surgery is a detailed, lengthy procedure often requiring ten or more hours.
Tumors are removed and destroyed using a variety of surgical techniques including argon beam coagulator, electro-evaporation, laser, and ultrasonic dissection.
The goal of cytoreductive surgery is to eliminate all tumor and metastatic tissues from the abdominal cavity, in order to effectively deliver intra-peritoneal heated chemotherapy (HIPEC).
Cytoreductive Surgery or Cytoreduction (CRS) is performed under general anesthesia. CRS time averages eight to ten hours.
A longitudinal incision is made in the abdomen. The abdomen, pelvis and organs therein are carefully inspected, during which time all operable visible and palpable tumors and tumor deposits are removed. The peritoneum is stripped.
Following surgery patients are admitted to the intensive care unit (ICU) for 24 hours or longer, depending on the individual patient. Patients are then transferred to regular hospitalization for an average of two weeks. This time period will vary depending on the individual.
Hemicolectomy is a surgical procedure involving the removal of a portion of the colon next to the appendix. This procedure may also include the removal of nearby blood vessels and lymph nodes at the same time.
Peritonectomy refers to stripping the parietal peritoneum and resecting structures at the sites that contain adenomucinosis. A combination of surgical techniques are utilized including organ resection, when necessary and tumor destruction via electro-evaporation and argon beam coagulation.
CRS surgery for Appendix Cancer and Pseudomyxoma Peritonei may include the following:
Removal of the omentum, spleen and gall bladder,
Right hemicolectomy, colectomy, removal of the rectum and sigmoid,
Stripping tumor from the surface of the liver,
Resection of the pancreas,
Gastrectomy (partial or total removal of the stomach)
Stripping the peritoneum from left and right hemidiaphragm;
Pelvic peritonectomy,
Ileostomy,colostomy or urostomy
Systemic Chemotherapy
Once thought to be ineffective for the treatment of Appendix Cancer and Pseudomyxoma Peritonei, cystemic chemotherapy treatment has become common during the past decade due to the development of several new colorectal cancer therapies.
Several systemic chemotherapies have become treatment options for Appendix cancer and pseudomyxoma peritonei patients. Systemic chemotherapy targets cancer cells throughout the body and is delivered throughout the bloodstream.
The "Chemo Pals' Resource & Support Group" is one of the largest, PMP Pal Resource Programs.
Participants in "Chemo Pals" are Pseudomyxoma Peritonei and Appendix Cancer patients who exchange information regarding the particular chemotherapy (ies) utilized, including results of their treatment regimens.
Is systemic chemotherapy an appropriate treatment for you?
Learn more about systemic chemotherapy
CRS (Cytoreductive Surgery) in conjunction with HIPEC: Articles and Abstracts
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Terence C. Chua, BScMed (Hons), MBBS 1, Kelly Thornbury, BMed 1, Akshat Saxena, BMedSc 1, Winston Liauw, MBBS, M Med Sci 2, Derek Glenn, MBBS 3, Jing Zhao, MD 1, David L. Morris, MD, PhD 1 *
1Department of Surgery, University of New South Wales, St George Hospital, Sydney, Australia
2Cancer Care Center, St George Hospital, Sydney, Australia
3Department of Radiology, St George Hospital, Sydney, Australia
Source: AMC Feb 2010
Treatment of Peritoneal Malignancies, including Pseudomyxoma Peritonei with CRS and HIPEC
CONCLUSION: It is important to recognize the role of and indications for CRS and HIPEC. Biologic factors of the disease and completeness of resection are important prognostic factors. Cytoreductive surgery, combined with intraperitoneal chemotherapy, can improve survival in selected patients with peritoneal-based malignancies.
Source:Department of Surgical Oncology, National Cancer Centre of Singapore, Singapore 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
12 Year Study of CRS and HIPEC for Pseudomyxoma Peritonei Treatment
Source: In Vivo, 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
HIPEC: Complexity
Source: Dr David L Bartlett,Journal of Surgical Oncology
Twelve year study of Pseudomyxoma Peritonei Treatment with CRS and HIPEC
Source: San Giuseppe Hospital, June 2009
Pleural Pseudomyxoma Peritonei Treatment with Thoracic CRS and HIPEC
Source: University of New South Wales, Australia, 2009
Pseudomyxoma Peritonei Treatment with CRS and HIPEC
Source: Universite de Montreal, Canada, 2009
HIPEC Treatment provided at St Agnes
Source: Dr Jesus Esquivel
Pseudomyxoma Peritonei Treatment with Cytoreductive Surgery and HIPEC
Source: British Journal of Surgery, Aug 2008
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Pseudomyxoma Peritonei Treatment with Chemo Hyperthermic Perfusion(CHPP)
Source: Pub Med 2009
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annuals of Surgical Oncology, 2008
International Consensus of PSMG for CRS and HIPEC
Source: Springerlink, Oct 2006
Alpha Index of Surgery Articles by Appendix Cancer Specialists
International listing of appendix cancer research and treatment articles and abstracts...
We provide the following abstracts and articles, published by, and/or written about the world's most experienced specialists in the treatment and research of Pseudomyxoma Peritonei, and Appendix Cancer. The full titles of some abstracts have been abbreviated due to space limitations.
Articles by Dr SA Ahrendt, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Fernando Arias, Colombia
Sleeve Gastrectomy
Source: Fundacion Santa Fe de Bogota
Abstracts by Dr Mario Baratti, Italy
Pseudomyxoma Peritonei Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
Articles by Dr David L Bartlett, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Dr David L Bartlett, Dr James Pingpank, Dr Steven Ahrendt
Source: Koch Cancer Treatment Center, UPMC
Profile for Dr David L Bartlett
Source: UPMC
Dr David L Bartlett: Koch Cancer Center
Source: UPMC
Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center
Articles by Dr Jean Bereder, France
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie. Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Wim Ceelen, Belgium
Dr Wim P Ceelen treats Pseudomyxoma Peritonei with HIPEC www.surgery.ugent.be
Articles by Dr Marcello Deraco, Italy
Pseudomyxoma Peritonei Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
HIPEC Treatment: Dott. Marcello Deraco: Pseudomyxoma Peritonei and Appendix Cancer
Source: Dott. Marcello Deraco
Articles by Dr D Elias, France
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Jesus Esquivel, USA
Learning Curve for CRS and HIPEC
Source: Journal of Surgical Oncology, August 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Physician Profile for Dr Jesus Esquivel
Source: St Agnes Hospital
Dr Jesus Esquivel:St Agnes Hospital
Source: St Agnes Hospital
Articles by Dr Jan Franko, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Click here to read Dr Jan Franko's profile
Source: Mercy Medical Center
Articles by Dr Gilly, France
Study of 300+ Patients Treated with CRS and PIC :
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients Source: Journal of Clinical Oncology 2008
Articles by Dr Joachim Jahne, Germany
CRS:Stategies to Reduce Post Op Morbidity and Complications
Source: Dr Joachim Jahne, April 2009
Articles by Dr Santiago Gonzalez-Moreno, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr Martin Goodman, USA
Dr Martin Goodman at Tufts University provides HIPEC
Source: Tufts University, Boston
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Laura Lambert, USA
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Articles by Dr Edward Levine, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
DPAM and HIPEC Treatment
Source: Wake Forest University
Articles by Dr Brian W Loggie, USA
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network
Articles by Dr Andrew Lowy, USA
Minimally Invasive Laparoscopic Treatment of Pseudomyxoma Peritonei
Source: UCSD, Dr Andrew Lowy, 2009
Dr Andrew Lowy: Moores Cancer Center
Source: UCSD
Treatment of Pancreatic Cancer
Source: Dr Andrew Lowy UCSD
Articles by Dr Paul Mansfield, USA
Profile for Dr Paul Mansfield
Source: MD Anderson
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Paul Mansfield, ASCO 2008
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Laparoscopic Staging for Gastric Cancer
Source: Dr Paul Mansfield, MDACC, Annals of Surgical Oncology, 2001
Laparoscopy for Surgical Oncology
Source: MDACC
Articles by Dr Brendan J Moran, United Kingdom
CRS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007
Articles by Prof David L Morris, Australia
New findings by Dr David L Morrris: CRS and Survival of Appendiceal Cancer Patients
Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients.
by Chua TC, Al-Alem I, Saxena A, Liauw W, Morris DL.
CONCLUSIONS: Cytoreductive surgery and intraperitoneal chemotherapy may achieve long-term survival in appendiceal malignancies with peritoneal dissemination for which the predictors of outcomes identified through this study may tailor the disease management to commit patients early toward this successful surgical strategy. Source:Ann Surg Oncol. 2011 Jun;18(6):1540-6. Epub 2011 Apr 14.
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris, 2009
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience.
This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
In vivo model for Pseudomyxoma Peritonei research
Source: Prof David L Morris, Sydney Australia, 2009
Articles by Dr Stefaan Mulier, Belgium
Dr Stefaan Mulier provides HIPEC treatment for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis
Source: Leopold Park Clinic in Brussels
Articles by Dr Herwart Mueller, German
CRS for Senior Patients
Source: Dr Herwart Mueller, Germany
Articles by Dr Garrett M Nash USA
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Articles by Dr Haydee Ojeda-Fournier, USA
Diagnostic Imaging of Pancreatic Cancer
Source: Dr Haydee Ojeda-Fournier, UCSD
Articles by Dr Gloria Ortega-Perez, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr James Pingpank, USA
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Articles by Prof Pompiliu Piso, Germany
Peritoneal Carcinomatosis Treatment (Study) with Tumor Honing Peptides
Source: Dept of Radiology, Germany 2009
Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
HIPEC Study with laboratory rats
Source: Deutscher Krebskongress, 2004
Articles by Dr B Ronnett, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Articles by Dr Armando Sardi, USA
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Published abstracts by Dr Armando Sardi
Source: Mercy Medical Center
Steps to Prepare for SurgerySource: Mercy Medical Center
Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center
Profile for Dr Armando Sardi
Source: Mercy Medical Center
Articles by Dr Perry Shen, USA
Dr Perry Shen at WFU provides HIPEC
Source: Wake Forest University
Articles by Dr Paul H Sugarbaker, USA
Mesenteric Cyst resulting in Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2010
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Epithelial appendiceal neoplasms (abstract with availability to purchase article in full)
Source: The Cancer Journal, 2009
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Management of mucinous urachal neoplasm presenting as Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2008
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Cytoreductive Surgery (includes graphic illustrations) Source: Dr Paul H Sugarbaker
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Appendix Cancer Prognosis
Source: Dr Paul H Sugarbaker, Washington Hospital Center
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul H Sugarbaker, 2005
Atlas of Appendix Cancer(includes graphic illustrations)
Source: Dr Paul H Sugarbaker
Articles referring to Dr Paul Sugarbaker and his patients
Source: PMP Pals' Network
Articles by Dr V J Verwaal,Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Cytoreduction and HIPEC Treatment for Appendix Cancer and Pseudomyxoma Peritonei (pdf)
Source: Netherlands Cancer Institute, Prof VJ Verwaal, 2006
Articles by Dr Tristan Yan, Australia
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Articles by Dr H Zeh, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr F Zoetmulder, Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008Are you scheduled for Appendix Cancer surgery? Would you like to talk with Appendix Cancer survivors who are living successful lives? Join PMP Pals! We'll provide you with Pal Mentors who will assist you today!
Hemicolectomy is a surgical procedure involving the removal of a portion of the colon next to the appendix. This procedure may also include the removal of nearby blood vessels and lymph nodes at the same time.
Peritonectomy refers to stripping the parietal peritoneum and resecting structures at the sites that contain adenomucinosis.
The peritoneum is the transparent serous membrane lining the cavity of the abdomen.
Ostomies: some patients require a temporary or permanent ostomy to assist them during recuperation.
The PMP Pals' Network provides many helpful resources, as well as Pal Mentors to assist you with your ostomy!
Thank you to "Pals" Bud and Ginny for sponsoring this page!
Thank you Bud & Ginny!
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright 2013 by PMP Pals' Network/All rights reserved. Update 05.19.13
